Zelira Therapeutics Recieves funding from Quincy Street
- Zelira Therapeutics (ZLD) raises US$5 million (around A$6.69) from US family office fund, Quincy Street Capital
- Under the placement, Quincy purchased around 79.9 million shares at six cents each
- Quincy Street has now become a substantial shareholder in Zelira with a 6.3 per cent stake
- Funds from the raise will be used to speed up the company’s growth initiatives
- The product line includes a mix of acne treatment and sunscreen, and known skin-boosting ingredients such as peptides and hyaluronic acid
- Zelira is up 20.5 per cent and is trading at 4.7 cents per share at 12:52 pm AEDT
